Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at Truist Financial

Truist Financial upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research report report published on Wednesday, MarketBeat.com reports. They currently have $49.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $58.00.

Several other analysts have also commented on COLL. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday. They issued an “outperform” rating and a $45.00 price target on the stock. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Barclays decreased their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. Needham & Company LLC cut their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $48.50.

Collegium Pharmaceutical Trading Down 0.0%

NASDAQ:COLL opened at $23.36 on Wednesday. Collegium Pharmaceutical has a 52-week low of $23.11 and a 52-week high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The stock has a fifty day simple moving average of $31.10 and a 200-day simple moving average of $33.75. The company has a market capitalization of $760.60 million, a PE ratio of 18.84 and a beta of 0.72.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.68 EPS. On average, equities research analysts expect that Collegium Pharmaceutical will post 6.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of the stock. Vident Advisory LLC raised its stake in Collegium Pharmaceutical by 1.9% during the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares during the period. Atom Investors LP increased its position in Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares in the last quarter. Assetmark Inc. increased its position in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in Collegium Pharmaceutical by 5.0% in the fourth quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company’s stock valued at $348,000 after buying an additional 356 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.